SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

Home・Lista de Ações・Genfit

Genfit

Fechado

SetorSaúde

8.52 -4.38

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

8.41

Máximo

8.95

Indicadores-chave
By Trading Economics
Rendimento	-66M -76M
Vendas	-3.6M 32M
EPS	-1.525
Margem de lucro	-237.939
Funcionários	188
EBITDA	-8M -7M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+69.27% upside

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	65M 438M
Abertura anterior	12.9
Fecho anterior	8.52

Sentimento de Notícias

By Acuity

45%

55%

139 / 345 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

3.566 / 4.12 Suporte e Resistência

Genfit Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

15 de mai. de 2026, 22:47 UTC

Ações em Alta

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 de mai. de 2026, 22:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 de mai. de 2026, 22:00 UTC

Grandes Movimentos do Mercado

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 de mai. de 2026, 18:09 UTC

Grandes Movimentos do Mercado

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 de mai. de 2026, 16:02 UTC

Ganhos

Grandes Movimentos do Mercado

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 de mai. de 2026, 14:55 UTC

Grandes Movimentos do Mercado

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15 de mai. de 2026, 14:43 UTC

Grandes Movimentos do Mercado

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15 de mai. de 2026, 22:17 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 de mai. de 2026, 21:59 UTC

Aquisições, Fusões, Aquisições de Empresas

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 de mai. de 2026, 21:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 de mai. de 2026, 21:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 de mai. de 2026, 21:16 UTC

Conversa de Mercado

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

15 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

15 de mai. de 2026, 20:19 UTC

Ações em Alta

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 de mai. de 2026, 19:41 UTC

Aquisições, Fusões, Aquisições de Empresas

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 de mai. de 2026, 19:35 UTC

Conversa de Mercado

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 de mai. de 2026, 19:33 UTC

Conversa de Mercado

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 de mai. de 2026, 18:35 UTC

Ganhos

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 de mai. de 2026, 17:28 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 de mai. de 2026, 16:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 de mai. de 2026, 16:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

15 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

15 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

15 de mai. de 2026, 15:55 UTC

Conversa de Mercado

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 de mai. de 2026, 15:20 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 de mai. de 2026, 15:20 UTC

Conversa de Mercado

Silver Plunges on Inflation Worries -- Market Talk

15 de mai. de 2026, 15:20 UTC

Ganhos

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15 de mai. de 2026, 14:33 UTC

Conversa de Mercado

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Comparação entre Pares

Variação de preço

Genfit Previsão

Preço-alvo

By TipRanks

69.27% parte superior

Previsão para 12 meses

Média 15.031 EUR 69.27%

Máximo 15.032 EUR

Mínimo 15.032 EUR

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Genfit - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

1 ratings

Comprar

Manter

Vender

Com base em 1 analistas que deram avaliações de ações para Genfit - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

3.566 / 4.12Suporte e Resistência

Recent bullish events outweigh bearish events.

Sentimento

By Acuity

139 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.